NASDAQ:BIIB - Biogen Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$230.18 +3.80 (+1.68 %)
(As of 04/22/2019 10:24 AM ET)
Previous Close$226.39
Today's Range$226.70 - $230.66
52-Week Range$216.12 - $388.67
Volume416,807 shs
Average Volume3.38 million shs
Market Capitalization$45.28 billion
P/E Ratio8.79
Dividend YieldN/A
Beta1.04
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. Further, it is involved in developing BIIB098, Opicinumab, and BIIB061 for MS and neuroimmunology; Aducanumab, Elenbecestat, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB092 and BIIB054 for treating Parkinson's disease and movement disorders; BIIB067, BIIB078, and BIIB110 to treat neuromuscular disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB104 for treating neurocognitive disorders; BIIB074 and BIIB095 for pain; and Dapirolzumab pegol, BG00011, and BIIB059 for treating other diseases, which are under various stages of development. The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc., Eisai Co., Ltd., Alkermes Pharma Ireland Limited, Bristol-Myers Squibb Company, Acorda Therapeutics, Inc., AbbVie Inc., C4 Therapeutics, University of Pennsylvania, Applied Genetic Technologies Corporation, and others. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Receive BIIB News and Ratings via Email

Sign-up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:BIIB
CUSIP09062X10
Phone617-679-2000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$13.45 billion
Cash Flow$32.2840 per share
Book Value$64.68 per share

Profitability

Net Income$4.43 billion

Miscellaneous

Employees7,800
Market Cap$45.28 billion
Next Earnings Date4/24/2019 (Confirmed)
OptionableOptionable

Biogen (NASDAQ:BIIB) Frequently Asked Questions

What is Biogen's stock symbol?

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

How were Biogen's earnings last quarter?

Biogen Inc (NASDAQ:BIIB) released its earnings results on Tuesday, January, 29th. The biotechnology company reported $6.99 earnings per share for the quarter, beating analysts' consensus estimates of $6.72 by $0.27. The biotechnology company had revenue of $3.53 billion for the quarter, compared to analysts' expectations of $3.39 billion. Biogen had a net margin of 32.94% and a return on equity of 40.53%. Biogen's revenue for the quarter was up 6.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $5.26 EPS. View Biogen's Earnings History.

When is Biogen's next earnings date?

Biogen is scheduled to release their next quarterly earnings announcement on Wednesday, April 24th 2019. View Earnings Estimates for Biogen.

How can I listen to Biogen's earnings call?

Biogen will be holding an earnings conference call on Wednesday, April 24th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

What guidance has Biogen issued on next quarter's earnings?

Biogen issued an update on its FY19 earnings guidance on Tuesday, January, 29th. The company provided EPS guidance of $28-29 for the period, compared to the Thomson Reuters consensus EPS estimate of $27.98. The company issued revenue guidance of $13.6-13.8 billion, compared to the consensus revenue estimate of $13.63 billion.Biogen also updated its FY 2019 guidance to $28.00-29.00 EPS.

What price target have analysts set for BIIB?

30 brokerages have issued twelve-month price targets for Biogen's shares. Their forecasts range from $210.00 to $400.00. On average, they anticipate Biogen's share price to reach $295.0442 in the next twelve months. This suggests a possible upside of 28.8% from the stock's current price. View Analyst Price Targets for Biogen.

What is the consensus analysts' recommendation for Biogen?

30 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 1 sell rating, 22 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Biogen.

What are Wall Street analysts saying about Biogen stock?

Here are some recent quotes from research analysts about Biogen stock:
  • 1. Cantor Fitzgerald analysts commented, ": Reiterate Neutral rating and $250 price target. Yesterday Novartis (NVS, NC) announced FDA approval of its oral S1P1 Mayzent (siponimod) in secondary progressive multiple sclerosis (SPMS), relapsing-remitting MS (RRMS), and clinically isolated syndrome using a priority voucher. We think this broad label is somewhat unexpected given that the pivotal study and regulatory filings were for SPMS patients, and a negative headline for competitors such as Biogen and possibly Celgene CELG, OW). With competitive efficacy and a cleaner label vs. NVS’ first gen S1P1 Gilenya, we think the key question is if and how quickly Mayzent can take share in RRMS post launch in early 2Q." (3/27/2019)
  • 2. HC Wainwright analysts commented, "Our PT of $363/share is based on a discounted cash flow analysis using a 10% discount rate and 2% growth rate, in line with the expected discount and growth parameters of a commercial multiproduct biotechnology company. Risks to our investment thesis and target price include: (1) failure in clinical studies; (2) failure to secure regulatory approval; and (3) a smaller than anticipated commercial opportunity due to market size, competition, and/or pricing." (2/19/2019)
  • 3. Mizuho analysts commented, "We updated our model post the 2Q18 earnings call and BAN2401 data last week." (7/31/2018)

Has Biogen been receiving favorable news coverage?

Media coverage about BIIB stock has been trending somewhat positive this week, according to InfoTrie Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Biogen earned a daily sentiment score of 1.2 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days.

Who are some of Biogen's key competitors?

What other stocks do shareholders of Biogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include Gilead Sciences (GILD), Netflix (NFLX), Celgene (CELG), NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Amgen (AMGN), Allergan (AGN), Micron Technology (MU) and Intel (INTC).

Who are Biogen's key executives?

Biogen's management team includes the folowing people:
  • Mr. Michel Vounatsos, CEO & Director (Age 57)
  • Mr. Jeffrey D. Capello, Exec. VP & CFO (Age 54)
  • Ms. Susan H. Alexander, Exec. VP, Chief of Legal & Corp. Services and Corp. Sec. (Age 62)
  • Dr. Michael D. Ehlers, Exec. VP and Head of R&D (Age 50)
  • Dr. Paul F. McKenzie, Exec. VP of Pharmaceutical Operations & Technology (Age 53)

Who are Biogen's major shareholders?

Biogen's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Waverton Investment Management Ltd (0.15%), Retirement Systems of Alabama (0.08%), Saratoga Research & Investment Management (0.08%), DNB Asset Management AS (0.07%), Gateway Investment Advisers LLC (0.06%) and Country Trust Bank (0.06%). Company insiders that own Biogen stock include Alexander J Denner, Alfred Sandrock, Brian S Posner, Michael D Ehlers, Michel Vounatsos, Paul J Clancy, Robert W Pangia and Susan H Alexander. View Institutional Ownership Trends for Biogen.

Which major investors are selling Biogen stock?

BIIB stock was sold by a variety of institutional investors in the last quarter, including Factory Mutual Insurance Co., Oakbrook Investments LLC, Calamos Advisors LLC, Strs Ohio, First Hawaiian Bank, Country Trust Bank, Waverton Investment Management Ltd and Trust Department MB Financial Bank N A. Company insiders that have sold Biogen company stock in the last year include Michael D Ehlers and Robert W Pangia. View Insider Buying and Selling for Biogen.

Which major investors are buying Biogen stock?

BIIB stock was purchased by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama, Virtu Financial LLC, DNB Asset Management AS, Pacer Advisors Inc., Saratoga Research & Investment Management, Hexavest Inc., Carnick & Kubik Group LLC and Ingalls & Snyder LLC. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner and Michel Vounatsos. View Insider Buying and Selling for Biogen.

How do I buy shares of Biogen?

Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biogen's stock price today?

One share of BIIB stock can currently be purchased for approximately $229.12.

How big of a company is Biogen?

Biogen has a market capitalization of $45.07 billion and generates $13.45 billion in revenue each year. The biotechnology company earns $4.43 billion in net income (profit) each year or $26.20 on an earnings per share basis. Biogen employs 7,800 workers across the globe.

What is Biogen's official website?

The official website for Biogen is http://www.biogen.com.

How can I contact Biogen?

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000 or via email at [email protected]


MarketBeat Community Rating for Biogen (NASDAQ BIIB)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  1,513 (Vote Outperform)
Underperform Votes:  891 (Vote Underperform)
Total Votes:  2,404
MarketBeat's community ratings are surveys of what our community members think about Biogen and other stocks. Vote "Outperform" if you believe BIIB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIIB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel